Bupropion Use in Bipolar Disorder with Mood Stabilizers
Bupropion can be used cautiously in patients with bipolar disorder when combined with a mood stabilizer, but it carries significant risk of precipitating manic/hypomanic episodes and is not FDA-approved for bipolar depression.
Critical FDA Warning
The FDA label explicitly states that antidepressant treatment can precipitate a manic, mixed, or hypomanic episode, with increased risk in patients with bipolar disorder 1. Prior to initiating bupropion, patients must be screened for bipolar disorder history and risk factors. Importantly, bupropion is NOT approved for treatment of bipolar depression 1.
Evidence-Based Recommendations
When Bupropion May Be Considered:
Bupropion should ONLY be used as adjunctive therapy to mood stabilizers, never as monotherapy 2, 3. The WHO guidelines specify that antidepressants in bipolar disorder must always be combined with mood stabilizers (lithium or valproate) 2.
- Bipolar II disorder: Lower risk of mood switching compared to Bipolar I 4, 5
- After mood stabilization: Only when depressive symptoms persist despite adequate mood stabilizer treatment 6
- No history of rapid cycling: Antidepressants are contraindicated in rapid cycling 7
- No prior antidepressant-induced switches: History of previous manic switches with antidepressants is a contraindication 7
Relative Safety Profile:
Bupropion has a LOWER risk of mood switching compared to venlafaxine and tricyclic antidepressants, but NOT as low as previously believed 8, 3, 4, 5. A 2006 randomized trial found:
- Venlafaxine had the highest switch risk (ratio of threshold switches to subthreshold hypomanias = 3.60-3.75)
- Bupropion had the lowest switch risk (ratio = 0.85-1.17)
- Sertraline was intermediate (ratio = 1.67-1.66) 4
However, a 2016 meta-analysis challenged this assumption, finding no significant difference in phase-shifting rates between bupropion and other antidepressants (P = 0.952) 8.
Switch Risk by Bipolar Type:
- Bipolar I: 30.8% threshold switch rate during treatment 4
- Bipolar II: 18.6% threshold switch rate during treatment 4
The risk is substantially higher in Bipolar I disorder, requiring extreme caution 3, 4.
Practical Clinical Algorithm
Step 1: Confirm Prerequisites
- Bipolar disorder diagnosis confirmed
- Patient currently on therapeutic dose of mood stabilizer (lithium, valproate, or antipsychotic)
- Mood stabilizer levels therapeutic and monitored 9
- No current manic/hypomanic/mixed symptoms
- No history of rapid cycling
- No prior antidepressant-induced mania
Step 2: Risk Stratification
HIGH RISK (avoid bupropion):
- Bipolar I disorder with history of severe mania
- Rapid cycling pattern
- Prior antidepressant-induced switches
- Mixed features present
MODERATE RISK (use with intensive monitoring):
- Bipolar I disorder, stable on mood stabilizer
- No prior switches
LOWER RISK (may consider):
- Bipolar II disorder
- Stable on mood stabilizer for ≥3 months
Step 3: Monitoring Protocol
- Week 1-2: Weekly assessment for emerging hypomania (irritability, decreased sleep need, increased energy, racing thoughts) 10
- Weeks 3-8: Biweekly monitoring
- Beyond 8 weeks: Monthly monitoring if stable
Step 4: Duration of Treatment
Discontinue bupropion after 2-3 months of remission 7. The 2007 pediatric guidelines recommend maintaining the regimen that stabilized acute symptoms for 12-24 months, but this applies to mood stabilizers, not antidepressants 9.
Critical Warnings
Neuropsychiatric Reactions:
Patients with bipolar disorder treated with bupropion have experienced delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion 1. These symptoms may require dose reduction or discontinuation 1.
Limited Efficacy Evidence:
A 2022 meta-analysis found no clinically significant improvement in response rate or depressive symptoms with adjunctive antidepressants in acute bipolar depression (SMD = -0.13,95% CI: -0.24 to -0.02) 11. Only 16.2% of patients achieved sustained antidepressant response without threshold mood switch 4.
Special Considerations
Comorbid cocaine dependence: A 2014 study showed bupropion 150 mg/day as add-on to valproate and aripiprazole improved both depression and cocaine use without increasing mania scores 6.
Comorbid ADHD: Stimulants can be added once mood is stabilized on mood stabilizers, but this is separate from antidepressant use 9.
Bottom Line
The risk-benefit ratio of bupropion in bipolar disorder is unfavorable for most patients 3. While it may have lower switch risk than some antidepressants, the absolute risk remains substantial (especially in Bipolar I), and efficacy is questionable. If used, it must be:
- Combined with therapeutic mood stabilizer doses
- Reserved for Bipolar II or carefully selected Bipolar I patients
- Monitored intensively for mood elevation
- Discontinued after 2-3 months of remission
- Never used in rapid cycling or mixed states